Stifel initiated coverage of Kestra Medical (KMTS) with a Buy rating and $28 price target Over the next three years, the firm sees Kestra’s Assure system as “primed for steady share-gain” and 40% sales growth year-over-year. Stifel views Kestra’s Assure wearable cardiac protection and monitoring system as a “compelling, clinically-differentiated solution” for the 850,000 U.S. patients at elevated-risk of sudden cardiac arrest.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMTS:
- Kestra Medical initiated with an Overweight at Piper Sandler
- Kestra Medical Technologies: Positioned for Growth with Next-Gen Wearable Cardioverter Defibrillator
- Buy Rating for Kestra Medical Technologies Ltd. Driven by Strong Growth Prospects and Strategic Market Positioning
- Kestra Medical initiated with a Neutral at Goldman Sachs